Adoptive Cell Therapy for Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia

Premal D. Lulla, Maksim Mamonkin, Malcolm K. Brenner

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations


Refractory and relapsed acute myeloid leukemia (AML) and T-lineage leukemia have poor prognosis and limited therapeutic options. Adoptive cellular immunotherapies are emerging as an effective treatment for patients with chemotherapy refractory hematological malignancies. Indeed, the use of unselected donor lymphocyte infusions has demonstrated successes in treating patients with AML and T-lineage leukemia post-allogeneic transplantation. The development of ex vivo manipulation techniques such as genetic modification or selection and expansion of individual cellular components has permitted the clinical translation of a wide range of promising cellular therapies for AML and T-cell acute lymphoblastic leukemia. Here, we will review clinical studies to date using adoptive cell therapy approaches and outline the major challenges limiting the development of safe and effective cell therapies for both types of acute leukemia.

Original languageEnglish (US)
Pages (from-to)199-207
Number of pages9
JournalCancer Journal (United States)
Issue number3
StatePublished - May 1 2019


  • Acute myeloid leukemia
  • T-cell acute lymphoblastic leukemia
  • adoptive cell therapy

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Adoptive Cell Therapy for Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia'. Together they form a unique fingerprint.

Cite this